Literature DB >> 26136929

Prognostic evaluation of preoperative serum C-reactive protein concentration in patients with epithelial ovarian cancer.

Yaping Lu1, Sen Huang1, Ping Li1, Bingyu Chen1, Weiling Liu1, Zhiqing Chen1, Fubo Yin2.   

Abstract

The aim of the present study was to evaluate correlations between preoperative C-reactive protein (CRP) serum concentration and the clinical-pathological parameters of epithelial ovarian cancer (EOC), as well as cancer antigen 125 (CA125) concentration, in patients with EOC. The preoperative serum CRP concentrations of 107 patients with EOC were compared with values of 44 control patients and defined as positive if values were >8 mg/l. Correlations between CRP expression and serum CA125 concentrations, International Federation of Gynecologists and Obstetricians (FIGO) staging, lymph node metastasis, ascites and size of postoperative residual lesions were evaluated for the EOC cases. A total of 69% (74/107) of the EOC cases were CRP-positive, with a mean serum CRP concentration of 14.32 mg/l (versus 2.18 mg/l in the control patients) (P<0.001). A rank correlation analysis showed a positive correlation between serum CRP and CA125 concentrations (P<0.001). The five-year survival rate of the CRP-positive patients with EOC was significant lower than that of the patients that were CRP-negative (33.3 vs. 75.8%, P<0.001). Non-parametric and multivariate analyses showed significant correlations between CRP concentrations and FIGO staging (P=0.001), lymph node metastasis (P=0.001) and ascites (P=0.033). In contrast to previous reports, the mean CRP serum concentration of the CRP-positive patients with EOC also correlated significantly with the CA125 values, and the increases in the CRP serum concentration in the Chinese patients were lower than those described for Caucasian EOC cases. In conclusion, the CRP serum concentration may be a useful clinical marker, solely or in combination with CA125, in patients with EOC.

Entities:  

Keywords:  C-reactive protein; cancer antigen 125; clinicopathological data; epithelial ovarian cancer; prognosis

Year:  2015        PMID: 26136929      PMCID: PMC4471804          DOI: 10.3892/etm.2015.2350

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  33 in total

1.  Race/ethnic variations in ovarian cancer mortality in the United States, 1992-1997.

Authors:  Holly L Howe; Ko-Hui Tung; Steven Coughlin; Rachel Jean-Baptiste; Joellyn Hotes
Journal:  Cancer       Date:  2003-05-15       Impact factor: 6.860

2.  C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam Study.

Authors:  Claire Siemes; Loes E Visser; Jan-Willem W Coebergh; Ted A W Splinter; Jacqueline C M Witteman; André G Uitterlinden; Albert Hofman; Huibert A P Pols; Bruno H Ch Stricker
Journal:  J Clin Oncol       Date:  2006-11-20       Impact factor: 44.544

3.  Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer.

Authors:  Lukas A Hefler; Robert Zeillinger; Christoph Grimm; Anil K Sood; Wen Fang Cheng; Angiolo Gadducci; Clemens B Tempfer; Alexander Reinthaller
Journal:  Gynecol Oncol       Date:  2006-06-05       Impact factor: 5.482

4.  Ascitic interleukin-12 is an independent prognostic factor in ovarian cancer.

Authors:  A G Zeimet; M Widschwendter; C Knabbe; D Fuchs; M Herold; E Müller-Holzner; G Daxenbichler; F A Offner; O Dapunt; C Marth
Journal:  J Clin Oncol       Date:  1998-05       Impact factor: 44.544

5.  Significance of preoperative C-reactive protein as a parameter of the perioperative course and long-term prognosis in squamous cell carcinoma and adenocarcinoma of the oesophagus.

Authors:  Ines Gockel; Kathrin Dirksen; Claudia-M Messow; Theodor Junginger
Journal:  World J Gastroenterol       Date:  2006-06-21       Impact factor: 5.742

6.  C-reactive protein concentrations and subsequent ovarian cancer risk.

Authors:  Meghan A McSorley; Anthony J Alberg; Diane S Allen; Naomi E Allen; Louise A Brinton; Joanne F Dorgan; Michael Pollak; Yuzhen Tao; Kathy J Helzlsouer
Journal:  Obstet Gynecol       Date:  2007-04       Impact factor: 7.661

Review 7.  Chronic inflammation and cancer.

Authors:  Emily Shacter; Sigmund A Weitzman
Journal:  Oncology (Williston Park)       Date:  2002-02       Impact factor: 2.990

8.  Measurement of the systemic inflammatory response predicts cancer-specific and non-cancer survival in patients with cancer.

Authors:  D C McMillan; M M Elahi; N Sattar; W J Angerson; J Johnstone; C S McArdle
Journal:  Nutr Cancer       Date:  2001       Impact factor: 2.900

9.  Systemic inflammatory response predicts survival following curative resection of colorectal cancer.

Authors:  D C McMillan; K Canna; C S McArdle
Journal:  Br J Surg       Date:  2003-02       Impact factor: 6.939

10.  C-reactive protein levels and subsequent cancer outcomes: results from a prospective cohort study.

Authors:  Kathy J Helzlsouer; Thomas P Erlinger; Elizabeth A Platz
Journal:  Eur J Cancer       Date:  2006-03-02       Impact factor: 9.162

View more
  4 in total

1.  The Glasgow Prognostic Score (GPS) is a novel prognostic indicator in advanced epithelial ovarian cancer: a multicenter retrospective study.

Authors:  Jiayu Zhu; Hua Wang; Cheng-Cheng Liu; Yue Lu; Hailin Tang
Journal:  J Cancer Res Clin Oncol       Date:  2016-08-26       Impact factor: 4.553

2.  Association between C-reactive protein level and subsequent risk of ovarian cancer: A meta-analysis of 13 cohorts in 1,852 ovarian cancer patients.

Authors:  Yan Wang; Zhiming Zhang; Jing Wang; Xiaowei Zhang
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.889

3.  C-Reactive Protein as a Prognostic Biomarker for Gynecologic Cancers: A Meta-Analysis.

Authors:  Yingying Yang; Xiu Li; Hui Qian; Guangci Di; Ruhua Zhou; Yuwei Dong; Wenyue Chen; Qingling Ren
Journal:  Comput Intell Neurosci       Date:  2022-10-11

4.  Role of the immune system in the peritoneal tumor spread of high grade serous ovarian cancer.

Authors:  Katharina Auer; Anna Bachmayr-Heyda; Nyamdelger Sukhbaatar; Stefanie Aust; Klaus G Schmetterer; Samuel M Meier; Christopher Gerner; Christoph Grimm; Reinhard Horvat; Dietmar Pils
Journal:  Oncotarget       Date:  2016-09-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.